 Group 2 Zemplar Standard Treatment: Patients in this group will receive the same combination of anti-rejection medications as the patients in Group 1 a-d above plus Zemplar, which is the medicine being studied, will also be started on the day of the transplant. Zemplar will be given as a capsule containing 1 microgram of Zemplar once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early. 